scholarly journals Analysis of adherence to treatment of patients with osteoporosis in the Omsk region (based on materials from the regional Center for the prevention and treatment of osteoporosis

2021 ◽  
Vol 23 (3) ◽  
pp. 17-23
Author(s):  
Elena A. Vilms ◽  
Evgeniya V. Dobrovolskaya ◽  
Maria S. Turchaninova ◽  
Elena A. Bykova
Keyword(s):  
Comparative Analysis ◽  
Zoledronic Acid ◽  
Chronic Conditions ◽  
Clinical Medicine ◽  
Osteoporotic Fractures ◽  
Adherence To Treatment ◽  
Treatment Of Osteoporosis ◽  
Regional Center ◽  
Prevention And Treatment

Background. Non-adherence to treatment, especially in chronic conditions, is a significant problem facing clinical medicine. Failure to adhere to treatment recommendations is often noted in the treatment of osteoporosis, which reduces the effectiveness of anti-osteoporotic drugs and a set of measures to prevent the occurrence of osteoporotic fractures.Aim. The aim of the study was to assess the adherence of patients of the Center for the Prevention and Treatment of Osteoporosis to treatment with anti-osteoporotic drugs of pathogenetic action.Materials and methods. This continuous observational study analyzed the adherence to long-term anti-osteoporotic therapy of patients observed at the Center for the Prevention and Treatment of Osteoporosis, the reasons for discontinuing treatment, doctors’ preferences in prescribing anti-osteoporotic therapy, reasons for changing the anti-osteoporotic drug. The study period is from July to December 2019.Results. During the analyzed period, 625 patients turned to the Center for the Prevention and Treatment of Osteoporosis. The preferences of doctors when prescribing anti-osteoporotic therapy have changed: the proportion of prescriptions for zoledronic acid and denosumab increased, mainly due to a reduction in the prescriptions of strontium ranelate, as well as risendronic acid, teriparatide, and calcitonin was no longer prescribed. Among 370 patients who received a therapeutic appointment (with an already known outcome of a therapeutic appointment), 40.0 ± 2.5% were non-compliant. Including: 9.7 ± 1.5% did not start taking the drug, interrupted the course ahead of schedule — 28.7 ± 2.4%. The termination of the course of therapy in 57.7% of cases was unauthorized, in another 42.3% it was associated with side effects. Patients started and continued further therapy with the initially prescribed drug in 53.8% of cases. As expected, the best adherence rates were found for drugs with parenteral administration once a year (zoledronic acid).Conclusions. Comparative analysis of the prescriptions of the main drugs of the pathogenetic action of patients of the center for the prevention and treatment of osteoporosis showed low compliance.

scholarly journals Zoledronic Acid Once-yearly: What Role in the Prevention of Non-vertebral Osteoporotic Fractures?

2010 ◽  
Vol 2 ◽  
pp. CMT.S4947
Author(s):  
Sheila Anne Doggrell
Keyword(s):  
Zoledronic Acid ◽  
Osteoporotic Fractures ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Glucocorticoid Treatment ◽  
Oestrogen Treatment ◽  
Treatment Of Osteoporosis ◽  
Hormone Sensitive ◽  
Low Levels ◽  
Single Intravenous Administration

Osteoporosis is the most common bone disease. Low levels of oestrogens or testosterone are risk factors for primary osteoporosis. The most common cause of secondary osteoporosis is glucocorticoid treatment, but there are many other secondary causes of osteoporosis. Osteoporosis can be secondary to anti-oestrogen treatment for hormone-sensitive breast cancer and to androgen-deprivation therapy for prostate cancer. Zoledronic acid is the most potent bisphosphonate at inhibiting bone resorption. In osteoporosis, zoledronic acid increases bone mineral density for at least a year after a single intravenous administration. The efficacy and safety of extended release (once-yearly) zoledronic acid in the treatment of osteoporosis is reviewed.

scholarly journals Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back

2012 ◽  
Vol 15 (2) ◽  
pp. 305 ◽  
Author(s):  
Pooneh Salari ◽  
Mohammad Abdollahi
Keyword(s):  
Atrial Fibrillation ◽  
Esophageal Cancer ◽  
Adverse Effects ◽  
Term Treatment ◽  
Duration Of Treatment ◽  
Treatment Of Osteoporosis ◽  
Beneficial Effects ◽  
Long Term Treatment ◽  
Prevention And Treatment

Purpose. Bisphosphonates are the main class of drugs widely used in prevention and treatment of osteoporosis. Along with the beneficial effects, recent studies point to the harms of long-term treatment with bisphosphonates. Methods. The most relevant articles reporting serious adverse effects of bisphosphonates were selected and reviewed with the aim of assessing the risk-benefit of bisphosphonates. We searched PubMed, Web of Science, and Scopus using keywords bisphosphonates, risk of fracture, atrial fibrillation, osteonecrosis jaw, esophageal cancer, and adverse effects with no time limitation. We limited our s research to English articles. Results. Our review shows that bisphosphonates reduce vertebral fractures in short term use while in long-term can cause osteonecrosis jaw, esophageal cancer, atrial fibrillation, and increase the risk of atypical fractures and probably adynamic bone disease. There is no consensus on the time limitation of bisphosphonate usage or its long term adverse effects. Thus, more studies on long-term side effects of bisphosphonates are highly recommended. In addition, new approaches for prevention and treatment of osteoporosis seem necessary. Conclusion. Prescribers should act cautionary and consider full assessment of risk-benefit and the duration of treatment. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

scholarly journals Role of zoledronic acid in the prevention and treatment of osteoporosis

2011 ◽  
pp. 89 ◽  
Author(s):  
Louis-Georges Ste-Marie ◽  
Ages Rakel ◽  
Andree Boucher ◽  
Louis-Georges Ste-Marie
Keyword(s):  
Zoledronic Acid ◽  
Treatment Of Osteoporosis ◽  
Prevention And Treatment

scholarly journals Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta–analysis

2012 ◽  
Vol 5 (9) ◽  
pp. 743-748 ◽  
Author(s):  
Jun Zhang ◽  
Ran Wang ◽  
Yi-Lei Zhao ◽  
Xiao-Hui Sun ◽  
Hong-Xing Zhao ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Meta Analysis ◽  
Treatment Of Osteoporosis ◽  
Prevention And Treatment

scholarly journals Use of alendronate in the therapy of osteoporosis

2020 ◽  
pp. 142-146
Author(s):  
O. B. Ershova
Keyword(s):  
Bone Fractures ◽  
Osteoporosis Treatment ◽  
Chain Structure ◽  
Side Chain ◽  
Adherence To Treatment ◽  
First Line ◽  
Treatment Of Osteoporosis ◽  
Proven Efficacy ◽  
Upper Gastrointestinal

Treatment of osteoporosis is a difficult task due to the need for long-term medication and maximum safety. The main goal of osteoporosis treatment is to prevent bone fractures. According to the national clinical guidelines for the treatment of osteoporosis, nitrogen-containing bisphosphonates are among the first-line drugs for the prevention and treatment of this disease. The diversity in the side chain structure determines the strength with which bisphosphonates bind to hydroxyapatite, are distributed, and remain in bone tissue for a certain time after treatment has been completed. They are the drugs of choice as they have proven efficacy in reducing the risk of fractures, and at the same time an acceptable safety profile. Bisphosphonates are the most well-known and studied drugs, successfully used in all countries for the treatment of various forms of osteoporosis. When using oral forms of bisphosphonates, the most expected undesirable phenomenon is esophagitis. The development of new forms of well-known and proven medicines that reduce adverse events and increase adherence to treatment is extremely important and promising. Of the latest achievements in this regard, it should be noted a new form of alendronate-Binosto-effervescent soluble tablet, the use of which reduces the risk of irritating effects on the upper gastrointestinal tract.

scholarly journals Clinical practice: the place of calcium supplements and vitamin D in the treatment of osteoporosis

2021 ◽  
Author(s):  
О.В. Добровольская ◽  
Н.В. Торопцова
Keyword(s):  
Vitamin D ◽  
Clinical Practice ◽  
Postmenopausal Women ◽  
Vitamin D Supplementation ◽  
Low Energy ◽  
Adherence To Treatment ◽  
Treatment Of Osteoporosis ◽  
Vitamin D Intake ◽  
Receive Treatment

Целью данного исследования было оценить место комбинированных препаратов кальция и витамина D в структуре лечения женщин в постменопаузе с остеопорозом, осложненным низкоэнергетическим переломом, и приверженность к ним в реальной клинической практике. Проанкетированы 196 женщин в постменопаузе (средний возраст 65,8 ± 9,1 года), перенесших низкоэнергетические переломы различных локализаций. Оценка структуры противоостеопоротической терапии и приверженности к лечению осуществлялась в течение 3 месяцев после перелома. 61%, 62%, 58% и 42% женщин получали противоостеопоротическую терапию через 4 месяца, 1, 2 и 3 года после перелома соответственно. Среди них только препаратами кальция и витамина D лечились 46%, 38%, 34% и 19% опрошенных соответственно. 49% респонденток, не получавших лечения по поводу остеопороза, в качестве причины указали отсутствие рекомендаций лечащего врача. Приверженными к приему препаратов кальция и витамина D в течение 1, 2 и 3 лет после перелома были 44%, 30% и 17% пациенток соответственно. Наиболее приверженными к лечению были лица, проконсультированные в специализированном центре по остеопорозу. Результаты исследования свидетельствуют о том, что женщинам после произошедшего перелома препараты кальция и витамина D назначались значимо чаще, чем патогенетические противоостеопоротические лекарственные средства. С увеличением срока после произошедшего перелома отмечалось снижение приверженности к приему кальция и витамина D, что демонстрирует необходимость более активного разъяснения пациенткам целесообразности длительного противоостеопоротического лечения, включая прием кальция и витамина D. The aim of this study was to assess the place of combined calcium and vitamin D preparations in the structure of treatment of postmenopausal women with osteoporosis complicated by low-energy fracture, and adherence to them in real clinical practice. A total of 196 postmenopausal women (mean age 65.8 ± 9.1 years) who had undergone low-energy fractures of various localizations were questioned. The structure of anti-osteoporotic therapy and adherence to treatment were assessed within 3 months after the fracture. 61%, 62%, 58% and 42% of women received anti-osteoporotic therapy at 4 months, 1, 2 and 3 years after the fracture, respectively. Among them, only calcium and vitamin D preparations were treated by 46%, 38%, 34% and 19% of the respondents, respectively. 49% of respondents who did not receive treatment for osteoporosis indicated the absence of recommendations from their doctor as the reason. Adherents to calcium and vitamin D supplementation for 1, 2 and 3 years after fracture were 44%, 30% and 17% of patients, respectively. The most adherent to treatment were those consulted at a specialized osteoporosis center. The results of the study indicate that after a fracture occurred to women, calcium and vitamin D preparations were prescribed significantly more often than pathogenetic anti-osteoporotic drugs. With an increase in the period after the fracture occurred, a decrease in adherence to calcium and vitamin D intake was noted, which demonstrates the need for a more active explanation to patients of the advisability of long-term anti-osteoporotic treatment, including calcium and vitamin D intake.

Sign in / Sign up

Export Citation Format

Share Document